Grace Therapeutics Files 8-K
Ticker: GRCE · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Grace Therapeutics, INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-actions
TL;DR
Grace Therapeutics filed a standard 8-K, no major news.
AI Summary
Grace Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting on "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Acasti Pharma Inc. until August 28, 2008, is incorporated in Delaware and headquartered in Princeton, New Jersey. This filing does not appear to disclose specific new events or financial details beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Grace Therapeutics, Inc. is meeting its regulatory reporting obligations. However, it does not provide new material information for investors at this time.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information that inherently increases risk.
Key Numbers
- 001-35776 — SEC File Number (Identifies the company's filing history with the SEC.)
- 0001444192 — Central Index Key (Unique identifier for the company in the SEC EDGAR system.)
Key Players & Entities
- Grace Therapeutics, Inc. (company) — Registrant
- Acasti Pharma Inc. (company) — Former company name
- September 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Princeton, New Jersey (location) — Principal executive offices
FAQ
What specific events are being reported under 'Other Events'?
The filing does not specify the nature of the 'Other Events' beyond listing it as an item information category.
Are there any new financial statements or exhibits included with this filing?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the specific contents are not detailed in the provided text.
When did Grace Therapeutics, Inc. change its name from Acasti Pharma Inc.?
The date of the name change from Acasti Pharma Inc. to Grace Therapeutics, Inc. was August 28, 2008.
Where are Grace Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.
What is the company's fiscal year end?
The company's fiscal year ends on March 31 (0331).
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-09-18 08:43:32
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share GRCE The Nasdaq Stock Mar
Filing Documents
- ef20055717_8k.htm (8-K) — 29KB
- ef20055717_ex99-1.htm (EX-99.1) — 20KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-25-035337.txt ( ) — 186KB
- grce-20250918.xsd (EX-101.SCH) — 4KB
- grce-20250918_lab.xml (EX-101.LAB) — 21KB
- grce-20250918_pre.xml (EX-101.PRE) — 16KB
- ef20055717_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On September 18, 2025, Grace Therapeutics, Inc. issued a press release announcing that the U.S. Patent and Trademark Office issued a Patent No. 12,414,943, titled "Nimodipine Parenteral Administration." The new method of use patent, published on September 16, 2025, covers the dosing regimen for I.V. administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104 and extends patent protection for GTx-104 to 2043. GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage patients. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated September 18 , 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GRACE THERAPEUTICS, INC. Date: September 18, 2025 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer